Highlights fourth quarter 2024:
• Q4 revenue reached USD 52.0 million, a 7% increase YoY, with adjusted EBITDA of USD 7.4 million, up from USD 2.5 million last year.
• Full-year 2024 revenue totalled USD 199.0 million, up 1% YoY, while adjusted EBITDA grew 29% to USD 29.0 million.
• Human Health Ingredients reported USD 25.5 million in revenue, a 25% increase YoY, driven by strong growth across most regions. Adjusted EBITDA rose 31% YoY to USD 9.6 million.
• Consumer Health Products generated USD 29.2 million in revenue, down 4% YoY, but remained stable compared to Q3 2024.
• Emerging Business delivered USD 2.2 million in revenue, up 5% YoY, driven by increased online sales. EBITDA loss narrowed to USD -1.1 million.
• The company implemented a restructuring and improvement program, with completion planned during 2025
“We delivered a decent quarter, achieving 7% revenue growth and a significant improvement in EBITDA compared to the same period last year. We are mostly proud of the continued momentum in our Human Health Ingredients segment, which has now delivered eight consecutive quarters of year-over-year revenue growth—demonstrating the consistency we have built since launching our turnaround program. Our core krill oil products have maintained strong performance, averaging 25% annual growth since 2022.”, said Matts Johansen, CEO of Aker BioMarine.
“2024 has held two different phases for Aker BioMarine. The first half of the year focused on successfully completing the Feed Ingredients segment transaction, while the second half has been dedicated to positioning the remaining business for long-term growth. Immediately post the transaction, we launched a restructuring and improvement program to enhance organizational, operational, and financial efficiencies. I want to extend my gratitude to all our employees for their dedication and hard work in making this possible.,” he concludes.
Outlook
Aker BioMarine remains focused on strengthening its core business and driving sustainable growth. The Human Health Ingredients segment continues to build on a solid foundation, positioning itself for further expansion, both geographically and in product offering. Meanwhile, Consumer Health Products expect to return to year-over-year revenue growth, reinforcing the segment’s long-term potential. The Emerging Business segment has made significant steps towards achieving cash break-even, and will continue to do so in 2025. Additionally, the company will implement organizational, operational, and financial efficiency from its improvement and restructuring program.
Attached is the quarterly presentation for Q4. Group reported financial figures can be downloaded in an excel from the company’s investor page: Investor - Analyst information
At 09:00 CET today, the management hosts a webcast. The webcasted presentation will be in English. To join, please use the link that is available at www.akerbiomarine.com/investor.
A replay of the presentation will be made available soon after the presentation at the same web address.
For further information, please contact
Christopher Robin Vinter, VP Strategic Finance & IR
Mobile: +47 911 60 820
Email: Christopher.vinter@akerbiomarine.com
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
About Aker BioMarine
Aker BioMarine is a leading human health and nutrition innovator that develops krill-derived products for consumer health and nutrition. Krill is a natural, powerful, and health-promoting source of nutrients from the pristine waters of Antarctica, and Aker BioMarine has a unique position in its industry. The ingredient portfolio consists of Superba Krill Oil, Lysoveta, FloraMarine, and PL+, as well as the consumer brand, Kori Krill. The innovative approach also extends into the spin-offs AION (reduce and recycle plastic waste across industries) and Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.